Tartronates: A new generation of drugs affecting bone metabolism

Journal of Bone and Mineral Research

Volumn 12, Issue 6, 1997, Pages 972-981

  Caselli, Gianfranco ^a   Mantovanini, Marco ^a   Gandolfi, Carmelo A ^a   Allegretti, Marcello ^a   Fiorentino, Simonetta ^b   Pellegrini, Luigi ^a   Melillo, Gabriella ^a   Bertini, Riccardo ^a   Sabbatini, Wilma ^a   Anacardio, Roberto ^a   Clavenna, Gaetano ^a   Sciortino, Giancarlo ^c   Teti, Anna ^c  

^a Chemistry Section   (Italy)

^b Consorzio BIOLAQ ^*  (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; DRUG VEHICLE; GLYCEROL 2 PHOSPHATE; OSTEOCALCIN; SALCATONIN; TARTRONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; BONE MINERALIZATION; CATTLE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; CALCITRIOL; CALCIUM; CATTLE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INFANT; MICE; MICE, INBRED C3H; OSTEOCLASTS; OSTEOGENESIS; RABBITS; RATS; TARTRONATES;

EID: 0030918613     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.6.972     Document Type: Article

References (40)

1. Fleisch H 1987 Bisphosphonates: History and experimental basis. Bone 8 (Suppl 1):S23-S28.
2. Gertz BJ, Holland SH, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG 1995 Studies on oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298.
3. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301-1305.
4. Schwitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962.
5. Avioli LV 1991 Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy. Calcif Tissue Int 49 (Suppl 2):S16-S19.
6. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM 1991 Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation and hormone-replacement therapy. N Engl J Med 325:1189-1195.
7. Riggs BL, Melton III LJ 1992 The prevention and treatment of osteoporosis. N Engl J Med 327:620-627.
8. Hauschka PV, Lian JB, Gallop PM 1975 Direct identification of the calcium-binding amino acid, γ-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72:3925-3929.
9. Pasteureau P, Vergnaud P, Meunier PJ, Delmas PD 1993 Osteopenia and bone-remodeling abnormalities in warfarin-treated lambs. J Bone Miner Res 8:1417-1426.
10. Szulc P, Chapuy M-C, Meunier PJ, Delmas PD 1993 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769-1774.
11. Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Chen S, Niinobu T, Ogihara T 1995 Participation of decreased circulating level of vitamin K in bone mineral loss of elderly men. J Bone Miner Res 10 (Suppl 1):S248 (abstract S388).
12. Kohlmeier M, Saupe J, Shearer M 1995 Risk of bone fracture in hemodialysis patients is related to vitamin K status. J Bone Miner Res 10 (Suppl 1):S361 (abstract M437).
13. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452.
14. Iwakura M, Hattori J, Arita Y, Tokushige M, Katsuki H 1979 Studies on regulatory functions of malic enzymes. VI. Purification and molecular properties of NADP-linked malic enzyme from Escherichia coli W. J Biochem 85:1355-1365.
15. Caggiano TJ, Zask A, Bex F 1991 Recent advances in bone metabolism and osteoporosis research. Ann Rep Med Chem 26:201-210.
16. Gandolfi C, Cotini L, Mantovanini M, Caselli G, Clavenna G, Omini C 1994 Tartronic acids, their acetalic ethers and Oesters. Patent WO 9410127.
17. Chambers TJ, Revell PA, Fuller K, Athanasou NA 1984 Resorption of bone by isolated rabbit osteoclasts. J Cell Sci 66:383-399.
18. Teti A, Tarquilio A, Grano M, Colucci S, Laforgia A, Mangini F, Zambonin-Zallone A 1991 Effect of calcium-phosphate-based materials on proliferation and alkaline phosphatase activity of newborn rat periosteal cells in vitro. J Dent Res 70:997-1001.
19. Prallet R, Male P, Neff L, Baron R 1992 Identification of a functional mononuclear precursor of the osteoclast in chicken medullary bone marrow cultures. J Bone Miner Res 7:405-414.
20. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG 1995 Ovariectomy enhances and estrogen replacements inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest 96:539-548.
21. Migliaccio S, Newbold RR, Bullock, BC, Jefferson WJ, Sutton FG, McLachlan JA, Korach KS 1996 Alteration of maternal estrogen levels during gestation affect the skeleton of female offspring. Endocrinology 137:2118-2125.
22. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ Bisphosphonates act on rat bone resorption through the mediation of osteoblast. 1993 J Clin Invest 91:2004-2011.
23. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P 1983 Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99.
24. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011.
25. van Beek E, Hoekstra M, van de Ruit M, Löwik CWGM, Papapoulos SE 1994 Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882.
26. Rodan GA, Fleisch HA 1996 Bisphosphonates: mechanism of action. J Clin Invest 97:2692-2696.
27. Baron R 1993 Anatomy and ultrastructure of bone. In: Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd Ed. Raven Press, New York, NY, U.S.A., pp. 3-9.
28. Kleerekoper M, Avioli LV 1993 Evaluation and treatment of postmenopausal osteoporosis. In: Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd Ed. Raven Press, New York, NY, pp. 223-229.
29. Klein BY, Gal I, Libergal M, Ben-Bassat H 1996 Opposing effects on mitochondrial membrane potential by malonate and levamisole, whose effect on cell-mediated mineralization is antagonistic. J Cell Biochem 60:139-147.
30. Klein BY, Gal I, Segal D 1993 Selection of malonate-resistant stromal cell-derived osteoprogenitor cell in vitro. J Cell Biochem 51:190-197.
31. Shapiro IM, Golub EE, Kakuta S, Hazelgrove J, Havery J, Chance B, Frasca P 1982 Initiation of enchondral calcification is related to changes in the redox state of hypertrophic chondrocytes. Science 217:950-952.
32. Loveridge N, Dean V, Goltzman D, Hendy GN 1991 Bioactivity of parathyroid hormone and parathyroid hormone-like peptide: Agonist and antagonist activities of amino-terminal fragments assessed by the cytochemical bioassay and in situ biochemistry. Endocrinology 128:1938-1946.
33. Sugiyama T, Ohashi T, Kusuhara S 1993 Inhibition of osteoclastic bone resorption by calcitonin in the cultured medullary bone of laying hens. Jpn Poult Sci 30:16-23.
34. King WR, Francis MD, Michael WR 1971 Effect of disodium ethane-1-hydroxy-1,1-diphosphonate on bone formation. Clin Orthop 78:251-270.
35. Tenebaum HC, Torontali M, Sukhu B 1992 Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13:249-255.
36. Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M 1995 Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10 (Suppl 1):129.
37. Bhattacharyya MH, Whelton BD, Stern PH, Peterson DP 1988 Cadmium accelerates bone loss in ovariectomized mice and fetal rat limb in culture. Proc Natl Acad Sci USA 85:8761-8765.
38. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R 1994 Interleukin-1 receptor antagonist and Tumor Necrosis Factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94:2397-2406.
39. Bain SD, Bailey MC, Celino DL, Lantry MM, Edwards MW 1993 High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse. J Bone Miner Res 8:435-442.
40. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Med 2:1132-1136.